{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:08:24Z","timestamp":1790820504584,"version":"4.1.0"},"reference-count":35,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:p>The Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) pathway has been identified as a key player in the pathophysiology of alopecia areata and a potential target for therapy. Here, we give a narrative review of what is known about Janus kinase inhibitors in alopecia areata. Several clinical trials as well as smaller studies have demonstrated hair regrowth and remission with oral Janus kinase inhibitors therapy, even in patients who failed conventional treatment. Baricitinib is the only US FDA-approved treatment for alopecia areata but data for other oral Janus kinase inhibitors such as tofacitinib, ruxolitinib and ritlecitinib are also promising. Fewer clinical trials have investigated topical Janus kinase inhibitors for alopecia areata, with many of them terminated early due to unfavourable results. Overall, Janus kinase inhibitors are an efficacious addition to the therapeutic arsenal for treatment-refractory alopecia areata. Further work is needed to examine the effects of long-term usage of Janus kinase inhibitors, the efficacy of topical Janus kinase inhibitors, as well as to identify biomarkers that could predict differential therapeutic responses to the various Janus kinase inhibitors.<\/jats:p>","DOI":"10.25259\/ijdvl_1093_2022","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T13:44:20Z","timestamp":1687441460000},"page":"799-806","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Janus kinase inhibitors for alopecia areata: A narrative review"],"prefix":"10.25259","volume":"89","author":[{"given":"Renee D.","family":"Haughton","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California, Davis, 3301 C St., Sacramento, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha M.","family":"Herbert","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Davis, 3301 C St., Sacramento, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ji-Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Davis, 3301 C St., Sacramento, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Downing","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Davis, 3301 C St., Sacramento, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siba P.","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, 3301 C St., Sacramento, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanual","family":"Maverakis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Davis, 3301 C St., Sacramento, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"10.25259\/IJDVL_1093_2022\/ref-1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/CCID.S53985","article-title":"Epidemiology and burden of alopecia areata: A systematic review","volume":"8","author":"Villasante Fricke","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","article-title":"Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review","volume":"85","author":"Toussi","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"10.25259\/IJDVL_1093_2022\/ref-4","doi-asserted-by":"publisher","first-page":"955035","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/BOR.0000000000000810","article-title":"Janus kinase-signal transducers and activators of transcription cell signaling in spondyloarthritis: Rationale and evidence for JAK inhibition","volume":"33","author":"Raychaudhuri","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-6","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jdcr.2019.07.005","article-title":"Treatment of severe alopecia areata with baricitinib","volume":"5","author":"Olamiju","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_1093_2022\/ref-7","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two Phase 3 Trials of Baricitinib for Alopecia Areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_1093_2022\/ref-8","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-9","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.25259\/IJDVL_1093_2022\/ref-10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","article-title":"Treatment of alopecia areata with tofacitinib","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-11","doi-asserted-by":"publisher","first-page":"e12844","DOI":"10.1111\/dth.12844","article-title":"Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients","volume":"32","author":"Serdaro\u011flu","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_1093_2022\/ref-12","year":"2021","journal-title":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions"},{"key":"10.25259\/IJDVL_1093_2022\/ref-13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_1093_2022\/ref-14","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.25259\/IJDVL_1093_2022\/ref-15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/ijd.13598","article-title":"Two cases of alopecia areata treated with ruxolitinib: A discussion of ideal dosing and laboratory monitoring","volume":"56","author":"Vandiver","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-16","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jaad.2018.08.040","article-title":"Ruxolitinib for the treatment of severe alopecia areata","volume":"80","author":"Liu","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-18","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-19","year":"2021","journal-title":"Pfizer announces positive top-line results from phase 2b\/3 trial of ritlecitinib in alopecia areata"},{"key":"10.25259\/IJDVL_1093_2022\/ref-20","year":"2022","journal-title":"FDA and EMA accept regulatory submission for Pfizer\u2019s ritlecitinib for individuals 12 years and older with alopecia areata"},{"key":"10.25259\/IJDVL_1093_2022\/ref-21","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.1111\/ijd.16316","article-title":"Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib","volume":"61","author":"Asfour","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-22","doi-asserted-by":"publisher","first-page":"e15346","DOI":"10.1111\/dth.15346","article-title":"Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report","volume":"35","author":"Cantelli","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_1093_2022\/ref-23","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1111\/ijd.16342","article-title":"Assessment of alopecia areata universalis successfully treated with upadacitinib","volume":"62","author":"Gori","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdcr.2022.02.027","article-title":"A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib","volume":"22","author":"Zhao","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_1093_2022\/ref-25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/ajd.13836","article-title":"Successful treatment of chronic severe alopecia areata with abrocitinib","volume":"63","author":"Bennett","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-26","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1080\/09546634.2022.2089323","article-title":"Janus kinase inhibitors and risk of internal malignancy in dermatomyositis","volume":"33","author":"Ji-Xu","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_1093_2022\/ref-27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-28","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical Ruxolitinib for the treatment of Alopecia Universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-29","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/ijd.14192","article-title":"Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study","volume":"57","author":"Bokhari","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-30","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jdcr.2018.07.018","article-title":"Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes","volume":"4","author":"Craiglow","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_1093_2022\/ref-31","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/ced.14615","article-title":"The status and outcomes of registered clinical trials for Janus kinase inhibitors in alopecia areata: Are unpublished trials being overlooked?","volume":"46","author":"Steele","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-32","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1111\/jdv.15383","article-title":"Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata","volume":"33","author":"Gordon","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-38","first-page":"83","article-title":"16384 ATI-501, a novel Janus kinase 1\/3 inhibitor, demonstrates hair growth in patients with alopecia areata: Results of a phase 2, randomized, double-blind, placebo-controlled trial. Abstract","author":"Gold","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1093_2022\/ref-43","doi-asserted-by":"publisher","first-page":"106257","DOI":"10.1016\/j.ejps.2022.106257","article-title":"Randomized, double-blinded, placebo-controlled phase I study of the pharmacokinetics, pharmacodynamics, and safety of KL130008, a novel oral JAK inhibitor, in healthy subjects","volume":"176","author":"Li","year":"2022","journal-title":"Eur J Pharm Sci"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/janus-kinase-inhibitors-for-alopecia-areata-a-narrative-review\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/janus-kinase-inhibitors-for-alopecia-areata-a-narrative-review\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T05:48:50Z","timestamp":1698472130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/janus-kinase-inhibitors-for-alopecia-areata-a-narrative-review\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":35,"alternative-id":["10.25259\/IJDVL_1093_2022"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_1093_2022","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"article-number":"799"}}